Carl Spana - Palatin Technologies President, Chief Executive Officer, Director
| PTN Stock | USD 1.13 0.06 5.61% |
CEO
Dr. Carl Spana Ph.D. is President, Chief Executive Officer, Director of the Company. He is cofounder of Palatin, was our Chief Executive Officer and President since June 14, 2000. He was a director of Palatin since June 1996 and was a director of our whollyowned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical VC firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana cofounded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at BristolMyers Squibb, a publiclyheld pharmaceutical company, where he was involved in scientific research in the field of immunology. He was previously a member of the board of the life science company AVAX Technologies, Inc since 2000.
| Age | 62 |
| Tenure | 24 years |
| Professional Marks | Ph.D |
| Address | Cedar Brook Corporate Center, Cranbury, NJ, United States, 08512 |
| Phone | 609 495 2200 |
| Web | https://palatin.com |
Carl Spana Latest Insider Activity
Tracking and analyzing the buying and selling activities of Carl Spana against Palatin Technologies stock is an integral part of due diligence when investing in Palatin Technologies. Carl Spana insider activity provides valuable insight into whether Palatin Technologies is net buyers or sellers over its current business cycle. Note, Palatin Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Palatin Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Carl Spana over three months ago Disposition of 2951 shares by Carl Spana of Palatin Technologies at 1.82 subject to Rule 16b-3 | ||
Carl Spana over three months ago Disposition of 5056 shares by Carl Spana of Palatin Technologies at 1.88 subject to Rule 16b-3 | ||
Carl Spana over three months ago Acquisition by Carl Spana of 66000 shares of Palatin Technologies subject to Rule 16b-3 | ||
Carl Spana over six months ago Disposition of 2337 shares by Carl Spana of Palatin Technologies at 7.0 subject to Rule 16b-3 |
Palatin Technologies Management Efficiency
The company has Return on Asset of (1.3196) % which means that on every $100 spent on assets, it lost $1.3196. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.232) %, meaning that it generated no profit with money invested by stockholders. Palatin Technologies' management efficiency ratios could be used to measure how well Palatin Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Equity is likely to grow to 280.03, though Return On Tangible Assets are likely to grow to (2.63). As of the 29th of November 2024, Non Current Assets Total is likely to grow to about 1.9 M, while Total Assets are likely to drop about 10.2 M.Similar Executives
| Found 6 records | CEO Age | ||
| David MBA | Salarius Pharmaceuticals | 61 | |
| Stephen JD | Pieris Pharmaceuticals | 48 | |
| Rachelle Jacques | Akari Therapeutics PLC | 53 | |
| CFA III | Checkpoint Therapeutics | 48 | |
| Samir MD | Akari Therapeutics PLC | 55 | |
| Lisa Conte | Jaguar Animal Health | 65 | |
Management Performance
| Return On Equity | -6.23 | ||||
| Return On Asset | -1.32 |
Palatin Technologies Leadership Team
Elected by the shareholders, the Palatin Technologies' board of directors comprises two types of representatives: Palatin Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Palatin. The board's role is to monitor Palatin Technologies' management team and ensure that shareholders' interests are well served. Palatin Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Palatin Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, COO, CFO | ||
| Carl Spana, President, Chief Executive Officer, Director | ||
| Joseph Hull, Independent Director | ||
| Angela Rossetti, Independent Director | ||
| Robert Jordan, Senior Operations | ||
| Stephen Esq, Chief Officer | ||
| Burns McClellan, Vice Relations | ||
| John Dodd, Senior Development | ||
| Anthony Manning, Independent Director | ||
| Alan Dunton, Independent Director | ||
| Robert deVeer, Independent Director | ||
| MST CPA, COO, CFO | ||
| James Hattersley, Senior Development | ||
| John Prendergast, Co-Founder, Chairman and Chairman of Nominating and Corporate Governance Committee | ||
| Arlene Morris, Independent Director | ||
| Stephen Wills, Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary | ||
| Michael MD, Chief Officer |
Palatin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Palatin Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.23 | ||||
| Return On Asset | -1.32 | ||||
| Operating Margin | (23.79) % | ||||
| Current Valuation | 20.18 M | ||||
| Shares Outstanding | 19.55 M | ||||
| Shares Owned By Insiders | 3.50 % | ||||
| Shares Owned By Institutions | 7.88 % | ||||
| Number Of Shares Shorted | 1.17 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 15.83 X |
Pair Trading with Palatin Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Palatin Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Palatin Technologies will appreciate offsetting losses from the drop in the long position's value.Moving against Palatin Stock
| 0.64 | BHC | Bausch Health Companies | PairCorr |
| 0.63 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.56 | HCM | HUTCHMED DRC | PairCorr |
| 0.54 | GANX | Gain Therapeutics | PairCorr |
| 0.5 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
The ability to find closely correlated positions to Palatin Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Palatin Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Palatin Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Palatin Technologies to buy it.
The correlation of Palatin Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Palatin Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Palatin Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Palatin Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palatin Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Palatin Stock, please use our How to Invest in Palatin Technologies guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palatin Technologies. If investors know Palatin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palatin Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.98) | Revenue Per Share 0.306 | Quarterly Revenue Growth (0.80) | Return On Assets (1.32) | Return On Equity (6.23) |
The market value of Palatin Technologies is measured differently than its book value, which is the value of Palatin that is recorded on the company's balance sheet. Investors also form their own opinion of Palatin Technologies' value that differs from its market value or its book value, called intrinsic value, which is Palatin Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palatin Technologies' market value can be influenced by many factors that don't directly affect Palatin Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palatin Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Palatin Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palatin Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.